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Glycemic variability (GV) is a physiologic phenomenon 
which refers to fluctuations in blood glucose (BG) levels 
over time. It can be described as within-day variability, with 
differences between fasting and postprandial BG values 
throughout a 24-hour period, and between-day variability.
GV is emerging as a measure of glycemic control, which 
may be a reliable predictor of complications. Results from a 
systematic literature review suggest that in type 2 diabetes, 
glucose variability is associated with development of micro-
vascular complications.1 Evidence is accumulating to indicate 
that high GV levels have deleterious effects beyond those of 
sustained chronic hyperglycemia, in terms of oxidative stress, 
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Abstract
Objective: The objective was to investigate glycemic variability indices in relation to demographic factors and common 
environmental lifestyles in a general adult population.
Methods: The A Estrada Glycation and Inflammation Study is a cross-sectional study covering 1516 participants selected 
by sampling of the population aged 18 years and over. A subsample of 622 individuals participated in the Glycation project, 
which included continuous glucose monitoring procedures. Five glycemic variability indices were analyzed, that is, SD, MAGE, 
MAG, CONGA1, and MODD.
Results: Participants had a mean age of 48 years, 62% were females, and 12% had been previously diagnosed with diabetes. 
In the population without diabetes, index distributions were not normal but skewed to the right. Distributional regression 
models that adjusted for age, gender, BMI, alcohol intake, smoking status, and physical activity confirmed that all indices 
were positively and independently associated with fasting glucose levels and negatively with heavy drinking. SD, MAGE, and 
CONGA1 were positively associated with aging, and MAG was negatively associated with BMI. None of the GVI studied 
were influenced by physical activity. Age-group-specific reference values are given for the indices.
Conclusions: This study yielded age-specific reference values for glucose variability indices in a general adult population. 
Significant increases were observed with aging. Heavy drinking of more than 140 g/week was associated with significant 
decreases in variability indices. No differences were found between males and females. These normative ranges provide a 
guide for clinical care, and may offer an alternative treatment target among persons with diabetes.
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diabetes complications, cardiovascular outcomes, and 
mortality,2-7 though some contradictory reports also exist.8,9
Determining the distribution of glycemic variability indi-
ces (GVI) in general populations is important for interpreting 
reference values. Almost all previously published data have 
come from patients with diabetes. Few studies into 24-hour 
BG profiles and glucose fluctuations have involved healthy 
subjects, and none have used subjects from a general 
population.10-13 In addition, the standard guidelines for defi-
nition and determination of reference intervals note that par-
titioning should be considered in cases where there are 
significant differences among subgroups defined by age, sex, 
and common exposures such as smoking or alcohol con-
sumption.14 Since the aim of treating diabetes is to restore 
glycemia to that of persons without diabetes, the generation 
of a metric of glycemic excursions should begin with an 
examination of the profiles of individuals without diabetes.15 
It is also crucial to define the boundary beyond which GVI 
take on a pathological significance.16
Taken together, it is imperative to have valid comparative 
frameworks for the interpretation of individual values and 
population distributions of GVI. Hence, this adult population-
based study investigated GVI levels in relation to demographic 
factors (age and sex) and common environmental lifestyles 
(physical activity, alcohol consumption, and smoking).
Methods
Study Design
The A Estrada Glycation and Inflammation Study (AEGIS) 
is a cross-sectional study which was performed in the munic-
ipality of A-Estrada, in Northwestern Spain. An age-strati-
fied random sample of the population aged 18 years and 
older was drawn from Spain’s National Health System 
Registry.
Any subjects who could not provide written informed 
consent was deemed ineligible to participate in the study; 
this group included patients with dementia, mental retarda-
tion, cerebrovascular disease, terminal cancer, or inability to 
communicate.
A total of 1516 subjects agreed to participate in the study 
(overall participation rate, 68%), made up of 678 men (45%) 
and 838 women (55%). Participation was lower, not only 
among men (65%) versus women (71%), but also in the 
youngest and oldest age groups. There were no significant 
differences in terms of age or residence (rural/urban) between 
subjects who did and did not agree to participate in the study. 
From November 2012 through March 2015, all subjects were 
successively convened for 1 day at the Primary Care Center 
for evaluation, which comprised (1) an interviewer-adminis-
tered structured questionnaire that included demographic 
and anthropometric data; (2) a lifestyle description, includ-
ing physical exercise, alcohol consumption, and smoking; 
and (3) fasting venous blood sampling.
In addition, study participants were invited to participate 
in the glycation project, which included continuous glucose 
monitoring (CGM) procedures. Additional exclusion criteria 
in this group were inability to fulfill the protocol, eating out, 
allergy to adhesives, or any concomitant medical condition 
that would likely affect evaluation of the performance of a 
device. A total of 622 subjects consented to undergo a 6-day 
period of CGM. Study profiles are summarized in Figure 1.
CGM Procedures
At the start of each monitoring period, a research nurse 
inserted a sensor (Enlite™, Medtronic, Inc, Northridge, CA, 
USA) subcutaneously into the abdomen, and instructed the 
participant in the use of the CGM device (iPro™, Medtronic, 
Inc, Northridge, CA, USA). This sensor measures subcuta-
neous tissue interstitial glucose levels continuously, record-
ing values every 5 min, within a range of 40-400 mg/dL 
(2.2-22.2 mmol/L). Participants were provided with a con-
ventional glucometer (OneTouch® Verio® Pro; LifeScan, 
Milpitas, CA, USA) as well as compatible lancets and test 
strips for calibrating the CGM. Subjects were asked to make 
at least 3 capillary BG measurements (usually before the 
main meals). The capillary BG readings were performed 
without checking the current CGM reading, and were also 
used for calibration of the iPro2 CGM system. On the 7th 
day the sensor was removed, and the data were downloaded 
and stored for further analysis. In any case where the number 
of data-acquisition “skips” per day totaled more than 2 hours, 
the entire day was discarded.
Of the 622 subjects enrolled in the study, 581 completed 
at least 2 days of monitoring. Forty-one subjects withdrew 
from the study due to noncompliance with protocol demands 
(n = 4), or difficulties in handling the device (n = 37). Itching 
was reported in 60 subjects and minor redness in 11. Swelling 
of the skin or bruises were never seen, and none of the 
patients reported pain at the sensor insertion site.
Classification of Alcohol Consumption and 
Smoking
Alcohol consumption was assessed using the standard drink-
ing unit system,17 which sums the number of glasses of wine 
(~10g), bottles of beer (~10g), and units of spirits (~20g). 
Individuals with an habitual alcohol consumption of 1-140 g/
week (n = 281, 48.4%) were considered light drinkers, and 
those with an alcohol consumption of >140 g/week (n = 71, 
12.2%) were considered heavy drinkers: the remainder 
(n = 229, 39.4%), made up of alcohol abstainers and very 
occasional alcohol drinkers, were pooled and included in the 
same group.
Tobacco smoking was recorded as the number of cigarettes 
regularly consumed per day. Consumers of at least 1 cigarette 
per day were considered smokers, as were individuals who had 
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quit smoking during the preceding year. Subjects were classi-
fied according to smoking status into the following 3 groups: 
(1) nonsmokers (n = 309, 53.2%), (2) ex-smokers (n = 154, 
26.5%), and (3) current smokers (n = 110, 20.3%).
Physical Activity Assessment
Subjects completed the International Physical Activity 
Questionnaire (short form),18 from which we calculated meta-
bolic equivalent of task and hours per week engaged in vigorous 
and moderate activities and walking, as described by Craig 
et al.19 We then classified them according to the 3 levels of physi-
cal activity: (1) “inactive” (n = 209, 36.0%), (2) “minimally 
active” (n = 223, 38.4%), and (3) “HEPA active” (health-enhanc-
ing physical activity; a high active category, n = 149, 25.6%).
Laboratory Determinations
The HbA1c was determined by high-performance liquid 
chromatography. All HbA1c values were converted to 
Diabetes Control and Complications Trial–aligned units.20 
Glucose was determined in fasting serum samples by the glu-
cose oxidase peroxidase method.
Measures of Glycemic Variability
After downloading the recorded data, 4 GVI were analyzed, 
that is, standard deviation (SD),15 mean amplitude of glycemic 
excursions (MAGE),15,21 mean absolute glucose (MAG) 
change per patient per hour,7 continuous overlapping net gly-
cemic action at 1 h (CONGA1),22 and the mean of daily differ-
ences (MODD).23 The mathematical formulae of the methods 
of assessment for glucose variability were taken from their 
original publications for inclusion in an R program, which is 
available free of charge for noncommercial use (Table 1).
Ethical Considerations
The present study was reviewed and approved by the 
Clinical Research Ethics Committee from Galicia, Spain 
Figure 1. Study flowchart.
Gude et al 783
Table 1. Function in R to Extract Glycemic Variability Indices From csv Files.
# index(data, d, n)
# Arguments
 # data is a database with covariates: id (identification), day (1, 2, 3, …), Glucose (mg/dl)
 # d, time (in min) between two consecutive glucose measurements
 # n, for CONGAn estimation (at 1, 2, … hours)
index <- function(data, d, n) {
  glucosemg <- data$Glucose
  day <- data$day
  id <- unique(data$id)
  glucose <- glucosemg/18
  N <- length(glucose) 
  m <- length(table(day)) # number of monitoring days
  Th <- 24*m # total time in hours
  # number of observations in 1 hour
  K <- dim(data[day = = 1, ])[1]
  dat <- cbind(c(1:N), data)
  colnames(dat)[1] <- “num” ; orden <- dat$num
  sd <- tapply(dat$glucose, dat$day, sd) # SD for each day
  IGV <- 120 # Ideal glucose value
  MG <- mean(glucosemg)
  SD <- sd(glucosemg)
  CV <- 100*SD/MG
  IQR <- IQR(glucosemg)
  M <- mean(abs(10*log10(glucosemg/IGV))^3) +
  (max(glucosemg)-min(glucosemg))/20 # M-value
  J <- 0.001*(MG + SD)^2 # J-Index (mg/dl)
 # J <- 0.324*(MG + SD)^2 # J-Index (mmol/l)
  FG <- 1.509*((log(glucosemg))^1.084 - 5.381)
  rl <- ifelse(FG < 0, 10*FG^2, 0)
  rh <- ifelse(FG > 0, 10*FG^2, 0)
  LBGI <- 1/N*sum(rl) # Low Blood Glucose Index
  HBGI <- 1/N*sum(rh) # High Blood Glucose Index
  LR = HR = NULL
  for (i in 1:m) {
  LR <- max(rl[day = = i])
  HR <- max(rh[day = = i])
  }
  ADRR <- 1/m*sum(LR + HR) # Average Daily Risk Ratio
  HYPO <- 100*mean((glucosemg < 70)) # Hypoglycaemia (%)
  HYPER <- 100*mean((glucosemg > 140)) # Hyperglycaemia (%)
  LI <- sum((glucose[1:N-1] - glucose[2:N])^2)/d # Lability Index
 # Glycemia Risk Assessment Diabetes Equation Score
  GRADE <- median(425*(log10(log10(glucose)) + 0.16)^2)
 # Continuous Overall Glycemic Action
  CONGA <- sd(glucose[(n+1):N] - glucose[1:(N-n)]
 # Mean of Daily Differences
  MODD <- sum(abs(glucose[(n+1):N] - glucose[(1+K):N])) / (K*m-1)
 # Area under the curve
  AUC <- (1/2*5*sum(glucosemg[1:N-1] + glucosemg[2:N])) / (m*24*60)
 # Mean Amplitude of Glycemic Excursions
  infl = maxi = mini = dif = downs = NULL
(continued)
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  for (i in 2:(N - 1)) {
  if ((glucosemg[i] - glucosemg[i - 1]) * (glucosemg[i + 1] - glucosemg[i]) < = 0) {
  infl = c(infl, i)}
  }
  infl <- c(infl,N)
  eps <- 8
  n_infl <- length(infl)
  for (j in 1:(n_infl)) {
  I1 <- (infl[j] - eps):(infl[j] + eps)
  I <- subset(I1, I1 < = max(infl) & 0 < I1)
  if (max(glucosemg[I]) = = glucosemg[infl[j]] |
   min(glucosemg[I]) = = glucosemg[infl[j]]) {
   maxi = c(maxi, infl[j]) 
   mini = c(mini, infl[j])
  }
  }
  mm <- c(sort(c(maxi, mini)), infl[n_infl])
  def <- ifelse(glucosemg[mm[1:(length(mm)-1)]] = = glucosemg[mm[2:length(mm)]],     NA, mm[1:length(mm)-1])
  def <- c(subset(def, def ! = “NA”), infl[n_infl]) 
  for (k in 1:m) {
  ii <- day[def] = = k
  deff = def[ii]
  diff = NULL
  for (j in 1:length(deff)) {
   diff <- c(diff, glucosemg[deff[j]] - glucosemg[def[j + 1]])
   }
  downs <- c(downs, (subset(diff, diff > 0 & diff > sd(k)))
  }
  MAGE <- sum(downs)/length(downs)
  values <- round(c(id, MG, SD, CV, IQR, M, AdM, J, LBGI, HBGI, ADRR,
  HYPO, HYPER, LI, MAG, GRADE, MAGE, CONGA, MODD, AUC), 6)
  return(values) 
 }
Table 1. (continued)
(CEIC2012-025). Written informed consent was obtained 
from each participant in the study, which conformed to the 
current Helsinki Declaration.
Statistical Analyses
The optimal GVI cut-off points for distinguishing subjects 
with and without diabetes were computed using the Youden 
J statistic.24
Different distributions were fitted to the observed distri-
bution of the different GVI, using Generalized Additive 
Models for Location Scale and Shape (GAMLSS).25 
GAMLSS allow for modeling, not only the mean response µ 
(ie, the location), but also other distribution parameters, such 
as standard deviation σ (ie, the scale) or skewness and kurto-
sis (ie, the shape parameters), as a function of a set of explan-
atory variables.
Goodness of fit was assessed by the Bayesian information 
criterion and Q-Q plots, to select the final model including 
the fitted distribution of GVI and the influence of covariates 
on the distribution parameters. Worm plots were used as a 
diagnostic tool to assess whether adjustment for kurtosis 
and/or skewness was required.26
Percentile curves of GVI as a function of the covariate 
age were calculated on the basis of the GAMLSS regres-
sion models that displayed the best goodness of fit. To 
facilitate the clinical use of our percentile curve data, we 
defined cut points at the 90th, 95th, and 97.5th percentiles 
for GVI.
All statistical analyses were performed using the R statisti-
cal software environment (version 3.0.2; R Foundation, http://




Participants had a mean age of 48 years (range 18 to 87), 
62% were females and 70 (12%) had been previously diag-
nosed of diabetes. Among patients with diabetes, 69% took 
oral antidiabetics, 4% insulin alone, and 17% insulin plus 
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oral drugs, and 10% were not taking insulin neither oral anti-
diabetics. Subjects with diabetes were older (61 ± 12 vs 46 ± 
14 years; P < .001), contained a higher proportion of men 
(50% vs 36%; P < .001), and had a higher BMI (31.2 ± 5.1 
vs 27.8 ± 5.1 kg/m2; P < .001) than those without diabetes. 
As expected, levels of fasting glucose and HbA1c were 
higher among subjects with diabetes than among those with-
out diabetes (134 ± 35 vs 88 ± 11 mg/dL and 7.1 ± 1.2 vs 5.3 
± 0.3%, respectively).
Distribution of Glycemic Variability Indices in the 
Population
Figure 2 shows nonparametric kernel density estimates of the 
GVI distributions in populations with and without diabetes. 
GVIs were highly correlated, showing correlation coefficients 
that ranged from 0.74 (between MAG and MODD) to 0.96 
(between SD and MAGE).
As expected, GVI were higher among subjects with dia-
betes than among those without diabetes. Table 2 also shows 
the distribution of cut-off values for all GVI, with their cor-
responding sensitivities, specificities and areas under the 
ROC curve (AUCs) for distinguishing between subjects with 
and without diabetes. All indices had a high discriminative 
ability for distinguishing individuals with and without diabe-
tes, with values ranging from 0.80 to 0.89 for AUCs.
GVI distributions were not normal but skewed to the right 
(Figure 2). In the population without diabetes, the best fit in 
GAMLSS was obtained as follows: for SD and MAG, using 
the log-normal distribution with parameters log(µ) and log(σ) 
Table 2. Glycemic Variability Indices in Individuals With and Without Diabetes, Cut-Off Levels (Youden Criterion) With Their 
Corresponding Sensitivity (Se), Specificity (Sp), and Area Under the ROC Curve for Distinguishing Individuals With and Without 
Diabetes.
Nondiabetes Diabetes Optimal cut point Se Sp
Area under the 
ROC curve (95% CI)
SD, mg/dL 14 (9, 24) 30 (13, 87) 23 0.76 0.94 0.88 (0.83, 0.93)
MAGE, mg/dL 26 (16, 45) 55 (24, 144) 40 0.77 0.90 0.89 (0.85, 0.94)
MAG, mg/dL 14 (9, 22) 21 (11, 37) 19 0.64 0.90 0.80 (0.74, 0.87)
CONGA1 0.74 (0.45, 1.25) 1.38 (0.66, 2.71) 1.17 0.70 0.93 0.87 (0.82, 0.92)
MODD 0.67 (0.40, 1.11) 1.26 (0.54, 3.29) 0.93 0.74 0.86 0.87 (0.81, 0.92)
Data describing glycemic indices in subjects with and without diabetes are medians and 5th-95th percentile ranges (in brackets).
Figure 2. Univariate density distributions of fasting glucose and glycemic variability indices (fasting glucose, SD, MAGE, MAG, CONGA, 
and MODD) in subjects with diabetes (red lines) and without diabetes (blue dotted lines).
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Table 3. Glycemic Variability Indices (Univariate Analysis) in Relation to Age, Sex, Body Mass Index, and Lifestyle, in the Population 
Without Diabetes.
n (%) SD MAGE MAG CONGA1 MODD
Age group (years) [.002] [.000] [.429] [.000] [.291]
 18-29 70 (14) 14 (8, 19) 23 (14, 40) 13 (8, 20) 0.68 (0.42, 1.13) 0.68 (0.42, 1.00)
 30-39 101 (20) 15 (9, 23) 24 (17, 44) 13 (8, 22) 0.70 (0.44, 1.25) 0.65 (0.42, 1.08)
 40-49 126 (24) 14 (9, 24) 26 (15, 45) 14 (8, 22) 0.74 (0.48, 1.29) 0.64 (0.39, 1.12)
 50-59 102 (20) 15 (9, 23) 28 (17, 44) 14 (8, 22) 0.78 (0.43, 1.21) 0.68 (0.43, 1.15)
 60 + 112 (22) 15 (9, 28) 28 (16, 49) 14 (9, 22) 0.80 (0.47, 1.44) 0.70 (0.38, 1.20)
Gender [.359] [.360] [.701] [.871] [.969]
 Female 326 (64) 15 (9, 26) 26 (17, 45) 14 (9, 22) 0.74 (0.46, 1.28) 0.66 (0.42, 1.13)
 Male 185 (36) 15 (8, 23) 26 (15, 43) 14 (9, 22) 0.76 (0.44, 1.22) 0.67 (0.38, 1.09)
Body mass index [.533] [.429] [.435] [.451] [.622]
 Normal weight 159 (31) 15 (9, 23) 26 (16, 42) 14 (9, 21) 0.75 (0.44, 1.22) 0.66 (0.40, 1.08)
 Overweight 194 (38) 15 (9, 25) 26 (16, 46) 13 (9, 22) 0.73 (0.44, 1.29) 0.66 (0.41, 1.12)
 Obese 158 (31) 15 (9, 26) 26 (16, 49) 14 (9, 22) 0.76 (0.45, 1.33) 0.68 (0.39, 1.16)
Alcohol intake [.052] [.055] [.058] [.247] [.086]
 Abstainers 198 (39) 15 (9, 26) 27 (17, 43) 14 (9, 22) 0.74 (0.47, 1.21) 0.67 (0.44, 1.14)
 Light drinkers 254 (50) 15 (9, 25) 26 (15, 48) 13 (9, 22) 0.74 (0.43, 1.32) 0.68 (0.42, 1.11)
 Heavy drinkers 59 (11) 14 (8, 20) 25 (15, 40) 13 (8, 20) 0.75 (0.43, 1.03) 0.61 (0.37, 1.05)
Smoking [.048] [.198] [.430] [.209] [.070]
 Nonsmokers 271 (53) 15 (9, 26) 26 (16, 46) 14 (9, 22) 0.69 (0.44, 1.26) 0.69 (0.44, 1.17)
 Ex-smokers 133 (26) 14 (8, 23) 26 (15, 45) 14 (8, 22) 0.74 (0.44, 1.32) 0.66 (0.37, 1.03)
 Smokers 107 (21) 14 (9, 22) 25 (15, 41) 13 (9, 21) 0.72 (0.47, 1.14) 0.65 (0.38, 1.04)
Physical activity [.292] [.091] [.292] [.473] [.551]
 Inactive 183 (36) 15 (9, 26) 27 (17, 47) 14 (9, 22) 0.74 (0.46, 1.29) 0.67 (0.45, 1.17)
 Minimally active 192 (37) 15 (9, 25) 27 (15, 46) 14 (9, 22) 0.74 (0.43, 1.23) 0.67 (0.40, 1.11)
 HEPA active 136 (27) 14 (9, 23) 25 (15, 43) 14 (8, 21) 0.74 (0.43, 1.21) 0.67 (0.40, 1.11)
Data are medians and 5th-95th percentile ranges (in brackets), and P values [in square brackets]. Individuals with alcohol consumption of 1-140 g/
week were considered light drinkers, and those with alcohol consumption > 140 g/week were considered heavy drinkers. Alcohol abstainers and very 
occasional alcohol drinkers were pooled in the same category. Normal weight, body mass index (BMI) < 25 kg/m2; overweight, BMI 25-30 kg/m2; obese, 
BMI > 30 kg/m2. HEPA active, health enhancing physical activity, a high active category.
modeled linearly; for MAGE and CONGA1, using the 
reverse Gumbel distribution with parameters µ and log(σ) 
modeled linearly; and for MODD, using the inverse Gaussian 
distribution with parameters log(µ) and log(σ) modeled 
linearly.
Relation of Glycemic Variability Measures With 
Age, Gender, BMI, and Lifestyle in the Population 
Without Diabetes
The univariate distribution of GVI in the population without 
diabetes according to gender, age, BMI, smoking habit, alco-
hol consumption, and physical activity is shown in Table 3.
In the population without diabetes, no significant differ-
ences were found between men and women in any of the 
GVI. However, significant age-related differences were 
found in the SD, MAGE, and CONGA1 indices, though not 
in MAG and MODD.
Drinkers of more than 140 g/week had the lowest GVI 
when compared with other categories of alcohol consumption. 
Light drinkers had similar GVI to abstainers. Ex-smokers had 
the lowest SD levels when compared with other categories of 
tobacco consumption. No significant differences were found 
in any of the indices in terms of BMI or physical activity.
To further elucidate the influence of variables that might 
be associated both with BG levels and with GVI, a multivari-
ate analysis was performed (See Table 4). Distributional 
regression models adjusted for age, gender, BMI, alcohol 
intake, smoking status, and physical activity confirmed that 
all indices were positively and independently associated with 
fasting glucose levels and negatively with heavy drinking. 
SD, MAGE, and CONGA1 were positively associated with 
aging, and MAG was negatively associated with BMI. None 
of the GVI studied were influenced by physical activity. 
Although MAG and MODD were not associated with age, 
age-specific reference values are given for all the studied 
indices (Table 5), and percentiles are shown in Figure 3.
Discussion
This article reports age-specific reference values for glu-
cose variability indices drawn from a general adult 
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population aged 18-90 years. According to our results, 
while GVI showed significant increases with aging and 
significant decreases in heavy drinkers of more than 140 
g/week, no differences were found between males and 
females. These results show that age- and alcohol-related 
changes in GVI are independent of potential confounders, 
such as levels of fasting glucose, BMI, smoking, and 
physical activity.
As expected, GVI were also found to differ significantly 
between individuals with and without diabetes. In the popu-
lation without diabetes, 90th percentile values for GVI were 
very close to the optimal cut-off points obtained by using the 
Youden criterion for discriminating between individuals 
with and without diabetes. AUCs registered values above 
0.8, thus showing that GVI could be useful tools for distin-
guishing between subjects with and without diabetes.
Table 5. Suggested Cut-Points for Glycemic Variability Indices Based on the Average Predicted Value Within Each Age Group and 90th, 
95th, and 97.5th Percentiles.
Age, years SD MAGE MAG CONGA1 MODD
 90 95 97.5 90 95 97.5 90 95 97.5 90 95 97.5 90 95 97.5
20 20 22 25 37 42 49 19 21 22 1.05 1.20 1.38 0.95 1.05 1.20
25 20 22 25 38 42 49 19 21 22 1.06 1.21 1.39 0.96 1.06 1.21
30 20 23 26 38 43 50 19 21 23 1.08 1.23 1.40 0.97 1.07 1.21
35 21 23 26 39 43 50 19 21 23 1.09 1.24 1.41 0.97 1.08 1.22
40 21 23 27 39 44 51 19 21 23 1.10 1.25 1.42 0.98 1.09 1.23
45 21 23 27 40 44 51 19 21 23 1.11 1.26 1.44 0.99 1.10 1.24
50 22 24 27 40 45 52 19 21 23 1.12 1.27 1.45 0.99 1.11 1.25
55 22 24 28 40 45 52 19 21 23 1.14 1.29 1.46 1.00 1.11 1.26
60 23 25 28 41 46 53 20 22 24 1.15 1.30 1.47 1.01 1.12 1.27
65 23 25 29 41 46 53 20 22 24 1.16 1.31 1.49 1.01 1.13 1.28
70 23 26 29 42 47 53 20 22 24 1.17 1.32 1.50 1.02 1.14 1.29
75 24 26 30 42 47 54 20 22 24 1.19 1.33 1.51 1.03 1.15 1.30
80 24 26 31 43 48 54 20 22 24 1.20 1.35 1.52 1.04 1.16 1.31
Table 4. Results of the Multivariate Distributional Analysis for Glycemic Variability Indices in Relation to Age, Sex, Body Mass Index, 
and Lifestyle, After Adjusting for Glucose Fasting Levels, in the Population Without Diabetes.
SD MAGE MAG CONGA1 MODD
 Coeff (SE) P value Coeff (SE) P value Coeff (SE) P value Coeff (SE) P value Coeff (SE) P value
Intercept 2.203 (0.117) .000 13.22 (2.844) .000 2.352 (0.106) .000 0.398 (0.097) .000 −0.840 (0.122) .000
Age, years 0.002 (0.001) .043 0.066 (0.026) .010 0.001 (0.001) .400 0.002 (0.001) .003 −0.001 (0.001) .518
BMI, kg/m2 0.001 (0.003) .685 −0.001 (0.074) .990 −0.006 (0.003) .017 −0.004 (0.002) .096 0.004 (0.003) .187
Gender (1. Men) −0.008 (0.029) .779 −0.115 (0.741) .877 0.032 (0.027) .227 0.010 (0.021) .651 0.007 (0.030) .819
Smoking
 Nonsmoker Reference Reference Reference Reference Reference
 Ex-smoker −0.058 (0.031) .061 −0.721 (0.751) .337 −0.017 (0.028) .551 0.010 (0.021) .943 −0.088 (0.031) .005
 Smoker −0.011 (0.034) .739 −0.076 (0.836) .926 0.005 (0.031) .878 0.002 (0.023) .143 −0.014 (0.035) .679
Alcohol consumption
 Abstainer Reference Reference Reference Reference Reference
 Light drinker −0.031 (0.430) .283 −1.098 (0.698) .116 −0.038 (0.026) .144 −0.029 (0.019) .143 −0.002 (0.029) .949
 Heavy drinker −0.151 (0.047) .001 −2.944 (1.166) .012 −0.144 (0.043) .001 −0.081 (0.033) .014 −0.133 (0.047) .005
Physical activity
 Inactive Reference Reference Reference Reference Reference
 Minimally active −0.028 (0.030) .339 −0.771 (0.717) .283 −0.014 (0.027) .599 −0.022 (0.020) .264 −0.032 (0.030) .287
 HEPA active −0.031 (0.033) .356 −0.737 (0.804) .359 −0.016 (0.030) .605 −0.007 (0.023) .747 −0.029 (0.034) .400
Glucose, mg/dL 0.005 (0.001)a 0.000 0.107 (0.035)a 0.003 0.005 (0.001)a 0.000 0.004 (0.001)a 0.008 0.005 (0.001)a 0.000
Sigma intercept (log) −1.252 (0.031) .000 1.921 (0.035) .000 −1.349 (0.031) .000 −1.658 (0.054) .000 −1.248 (0.049) .000
Mu link Log Identity Log Identity Log
Distribution type Log normal Reverse Gumbel Log normal Reverse Gumbel Inverse Gaussian
aSplines used for parameter estimation.
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Figure 3. Percentile curves (2.5, 5, 10, 25, 50, 75, 90, 95, 97.5) for glycemic variability indices (SD, MAGE, MAG, CONGA1, and 
MODD) and fasting glucose levels in the population without diabetes.
Most studies investigating reference values for glucose 
variability have been conducted on patients with diabetes, 
with few having addressed healthy subjects, and none -at 
least to our knowledge- having addressed a representative 
sample of the general population. In the largest study pub-
lished to date, which involved 434 healthy volunteers, 
Zhou et al found that SD and MAGE were non-normally 
distributed within the population and tended to increase 
with age, and that neither SD nor MAGE showed a signifi-
cant difference between men and women.10 Median values 
for both parameters were 0.75 mmol/L (14 mg/dL) and 
1.73 mmol/L (31 mg/dL),11 similar to those obtained by us 
(SD 15 mg/dL, MAGE 26 mg/dL) and by the study con-
ducted by the Juvenile Diabetes Research Foundation on 
74 healthy individuals without diabetes (SD 14 mg/dL, 
MAGE 28 mg/dL).12 In the latter, however, measures of 
glucose variability were not influenced by age. Similar 
results were also reported by Hill et al for MAGE but not 
for SD, in a study undertaken on adult subjects without 
diabetes in different ethnic groups.13 Unlike Zhou et al, 
who recommend a unified cut-off point for the normal ref-
erence values of the CGM parameters without differentia-
tion by age or sex,10 our study indicates cut-off points that 
vary with aging.
Different indices have been proposed for assessing GV, and 
no consensus has yet been reached as regards which are clini-
cally most useful. An US expert panel of diabetes specialists 
met in 2012 to discuss recommendations for standardization of 
analysis and presentation of glucose monitoring data. The 
majority (69%) of panel members indicated that SD was the 
most widely used and understood metric for assessing and 
reporting GV.27
In addition to SD, MAGE is a popular metric to quantify 
glucose variability.1,9-11,15 MAGE has been criticized on a 
number of grounds: (1) the qualifying limit of 1 SD is arbi-
trary; (2) its calculation is operator-dependent when a 
graphical approach is used; and (3) only the ascending or 
descending limb is used for its calculation.28 Another criti-
cism of MAGE found is its high correlation with SD, in this 
study 0.96. To exclude operator-dependent influences, we 
developed a computer software program for calculating 
MAGE values, based on the criterion that descending glu-
cose excursions exceed 1 SD of the arithmetic mean of 
24-hour periods. However, in a study evaluating software 
programs for the calculation of MAGE, Sechterberger et al 
found varying agreement among 4 available programs 
when applied to the same set of continuous glucose moni-
toring (CGM) traces, which would add other limitation to 
the previously reported.29 CONGA was the first GV metric 
to be specifically designed for CGM data.22 As CONGA 
does not require arbitrarily defined glucose cut-offs or 
changes in glucose levels, this approach provides a more 
objective assessment of GV over short time intervals. The 
absolute mean of daily differences (MODD) was developed 
to evaluate interday variability;23 this approach calculates 
the mean absolute value of the differences between glucose 
values on 2 consecutive days at the same time. However, 
the timing of meals can greatly affect MODD scores, mak-
ing a strict dietary regimen essential for accurate 
monitoring.
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As in the case of populations with diabetes, GVI are not 
symmetrically distributed: the larger values are further away 
from the mean than the smaller values, which means that the 
normal distribution might not be appropriate to fit GV data. 
Percentile curves were calculated using the so-called 
GAMLSS, developed by Rigby and Stasinopoulos.25 This 
method is an extension of the least mean squares method for 
modeling age-dependent GVI distribution, while accounting 
for the dispersion, kurtosis and, in particular, skewness of 
this distribution.
An interesting finding of our study is that, in free living 
conditions, consumers without diabetes of more than 140 g 
of alcohol per week showed lower GVI than did abstainers 
without diabetes and light drinkers. Alcohol consumption is 
a recognized risk factor for hypoglycemia in individuals with 
type 1 diabetes,30 and a recent meta-analysis showed that 
moderate alcohol consumption decreased fasting insulin 
concentrations among subjects without diabetes.31
Physical activity is widely recognized as an important 
component of a healthy lifestyle. In the present study, physi-
cal activity showed no association with any GVI. In a clinical 
trial on patients with type 1 diabetes, Kapitza et al32 found no 
differences in the glucose profiles with respect to the exercise 
challenge and some studies have shown that subjects with 
normal glucose tolerance do not improve insulin sensitivity, 
glucose regulation, or insulin release in response to exercise 
interventions.33
Our study has several limitations. First, the fact that these 
curves were derived from a cross-sectional study means that 
they provide accurate GV values in a European population 
but no information about the evolution of GV over time. 
Second, at the present time, the reference value database 
does not contain outcome data. Whether the reference values 
should be used as cut-off values for treatment remains to be 
discussed. Prospective studies and clinical trials are needed 
to determine whether percentile-based GVI have a role in 
identifying patients at higher risk of developing cardiovascu-
lar complications. Taken together with the long time span of 
recruitment, this could increase the scattering of the refer-
ence values provided; on the other hand, however, it also 
improves the external validity of our results.
Conclusions
These age-specific reference values for GVI may well serve 
as an orientation of glucose variability values in adult popu-
lations without diabetes in the context of standard medical 
practice.
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